These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 14621608

  • 1. [Comparative clinical and economic efficiency of new generation proton pump inhibitors in the treatment of gastroesophageal reflux].
    Starostin BD, Starostina GA.
    Eksp Klin Gastroenterol; 2003; (5):35-9. PubMed ID: 14621608
    [No Abstract] [Full Text] [Related]

  • 2. [Some comparative aspects of treating the gastroesophageal reflux disease eradication].
    Minushkin ON, Maslovskiĭ LV, Anikina NIu.
    Eksp Klin Gastroenterol; 2004; (3):45-8, 104. PubMed ID: 15560401
    [Abstract] [Full Text] [Related]

  • 3. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J, Dodd S, Durkin M, Sloan S.
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [Abstract] [Full Text] [Related]

  • 4. Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
    Gregor JC.
    Am J Manag Care; 2000 Aug; 6(8):934-5. PubMed ID: 11186505
    [No Abstract] [Full Text] [Related]

  • 5. Effectiveness of proton pump inhibitors: beyond cost.
    Katz PO.
    Rev Gastroenterol Disord; 2004 Aug; 4 Suppl 4():S8-S15. PubMed ID: 15580146
    [Abstract] [Full Text] [Related]

  • 6. [Reflux therapy in the elderly].
    Krankenpfl J; 2005 Aug; 43(7-10):182. PubMed ID: 16515255
    [No Abstract] [Full Text] [Related]

  • 7. [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
    Maev IV, Kucheriavyĭ IuA, Danilin MS.
    Eksp Klin Gastroenterol; 2003 Aug; (5):10-2, 192. PubMed ID: 14621603
    [Abstract] [Full Text] [Related]

  • 8. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
    Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP.
    Aliment Pharmacol Ther; 2006 May 15; 23(10):1473-7. PubMed ID: 16669962
    [Abstract] [Full Text] [Related]

  • 9. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ, Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GN, Smout AJ.
    Aliment Pharmacol Ther; 2004 Aug 15; 20(4):451-8. PubMed ID: 15298640
    [Abstract] [Full Text] [Related]

  • 10. [Basic principles of successful GERD (gastroesophageal reflux disease) therapy].
    Krankenpfl J; 2005 Aug 15; 43(1-3):67. PubMed ID: 15912855
    [No Abstract] [Full Text] [Related]

  • 11. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON, Maslovskiĭ LV, Anikina NIu, Shuleshova AG.
    Eksp Klin Gastroenterol; 2005 Aug 15; (2):29-35. PubMed ID: 15932152
    [No Abstract] [Full Text] [Related]

  • 12. Asymptomatic giardiasis--an association with proton pump inhibitors?
    Mukherjee S.
    Am J Gastroenterol; 2000 Dec 15; 95(12):3666-7. PubMed ID: 11151928
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of reflux disease. An international consensus conference put things in its place].
    Weber R.
    Rev Med Suisse Romande; 2003 Sep 15; 123(9):3p. PubMed ID: 15095598
    [No Abstract] [Full Text] [Related]

  • 14. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A, Wruble LD, Humphries TJ.
    Am J Gastroenterol; 2000 Aug 15; 95(8):1894-9. PubMed ID: 10950032
    [Abstract] [Full Text] [Related]

  • 15. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
    Inadomi JM, McIntyre L, Bernard L, Fendrick AM.
    Am J Gastroenterol; 2003 Sep 15; 98(9):1940-4. PubMed ID: 14499769
    [Abstract] [Full Text] [Related]

  • 16. [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
    Khavkin AI, Zhikhareva NS, Rachkova NS, Babaian ML, Volynets GV, Khanakaeva ZK.
    Eksp Klin Gastroenterol; 2004 Sep 15; (2):53-6. PubMed ID: 15462323
    [No Abstract] [Full Text] [Related]

  • 17. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.
    Wang YR, Pauly MV, Lin YA.
    Am J Manag Care; 2003 Oct 15; 9(10):686-96. PubMed ID: 14572179
    [Abstract] [Full Text] [Related]

  • 18. [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
    Morozov SV, Tsodikova OM, Isakov VA, Tereshchenko SG, Gushchin AE, Shipulin GA.
    Ter Arkh; 2005 Oct 15; 77(2):21-5. PubMed ID: 15807445
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y, Yoshino T, Shio S, Hayakumo T, Kawai K.
    Nihon Rinsho; 2004 Aug 15; 62(8):1504-9. PubMed ID: 15344541
    [Abstract] [Full Text] [Related]

  • 20. Laryngopharyngeal reflux symptoms improve before changes in physical findings.
    Belafsky PC, Postma GN, Koufman JA.
    Laryngoscope; 2001 Jun 15; 111(6):979-81. PubMed ID: 11404607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.